Note 8 — Restructuring Plans

In 2017, Abbott management approved restructuring plans as part of the integration of the acquisition of St. Jude Medical into the cardiovascular and neuromodulation segment to leverage economies of scale and reduce costs. In the first three months of 2017, charges of approximately $121 million, including one-time employee termination benefits were recorded as Selling, general and administrative expense. Abbott also assumed restructuring liabilities of approximately $20 million as part of the St Jude Medical acquisition. The following summarizes the activity for the first three months of 2017 related to these actions and the status of the related accrual as of March 31, 2017:

(in millions)
Liabilities assumed as part of business acquisition	$	20
Restructuring charges recorded in 2017	121
Payments and other adjustments	(43		)

Accrued balance at March 31, 2017	$	98

From 2014 to 2017, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional and established pharmaceuticals businesses. In the first three months of 2017, charges of approximately $10 million were recognized, of which approximately $6 million is recorded in Research and development and approximately $4 million as Selling, general and administrative expense. The following summarizes the activity for the first three months of 2017 related to these restructuring actions and the status of the related accrual as of March 31, 2017:

(in millions)
Accrued balance at December 31, 2016	$	66
Restructuring charges recorded in 2017	10
Payments and other adjustments	(15		)

Accrued balance at March 31, 2017	$	61